Hanover, Germany

Hildegard Büning

This inventor holds 4 USPTO granted patents and 4 published patent applications and 2 EPO patents. Top assignees: Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.v., Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.v., Medizinische Hochschule Hannover. Active years: 2023-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hildegard Büning. Retrieved from https://idiyas.com/inventor/hildegard-büning

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 

% Patents Active = 75.0

 

Average Co-Inventor Count = 3.3

ph-index = 1


Company Filing History:


Years Active: 2023-2026

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Hildegard Büning: Innovator in Gene Therapy

Introduction

Hildegard Büning is a prominent inventor based in Hannover, Germany. She has made significant contributions to the field of gene therapy, particularly through her work with adeno-associated viruses (AAV). With a total of 4 patents, her innovations are paving the way for advancements in medical treatments.

Latest Patents

Büning's latest patents include groundbreaking work on AAV vectors. The first patent relates to an adeno-associated virus that includes an insertion of at least 6-8 amino acids between specific positions of a defined sequence. This invention envisions the use of AAVs as a medicament and includes pharmaceutical compositions that incorporate these AAVs. Additionally, it discusses the in vitro use of AAV for transducing the nucleus of retinal cells, along with methods for screening insertion sequences and kits that comprise the AAV.

The second patent focuses on mutated adeno-associated viral capsid proteins. This invention allows for the chemical coupling of ligands, nanoparticles, or drugs via thioether binding. It describes a mutated AAV capsid protein where a non-cysteine amino acid is substituted with a cysteine, which is exposed on the outer surface of the AAV particle. The patent also identifies a nucleic acid encoding this capsid protein and discusses methods for modifying mutated AAV particles.

Career Highlights

Throughout her career, Hildegard Büning has worked with notable organizations such as Vigeneron GmbH and Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Her work in these institutions has significantly contributed to the advancement of gene therapy technologies.

Collaborations

Büning has collaborated with esteemed colleagues, including Stylianos Michalakis and Martin Biel. These partnerships have fostered innovation and research in the field of gene therapy.

Conclusion

Hildegard Büning's contributions to gene therapy through her patents and collaborations highlight her role as a leading inventor in the field. Her work continues to inspire advancements in medical science and therapeutic applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…